HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Svennberg E et al. Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference. Europace, 15 Dec 2025. DOI: ...

Key takeawaysAn international panel of more than 80 experts has issued updated guidance to improve care for atrial fibrillation (AF) patients ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Antiarrhythmic drugs can cause new, potentially deadly heart arrhythmias. Amiodarone is effective but can cause serious side effects and requires careful monitoring. Multaq cannot be used in people ...

Dr Emma Svennberg, cardiologist in Stockholm and first author of the consensus paper, noted that modern AF care requires a more streamlined and holistic approach. She highlighted the need to address ...

In this installment of Atrial Fibrillation (AFib) and Antiarrhythmic Drugs (AADs) series, Dr. Suneet Mittal interviews Dr. Jeff Healey about evidence supporting the guidelines and how they compare to ...